Advanced healthcare materials · 2025
Hybrid Ultrasound-Enhanced and Self-Cascade-Catalysis-Mediated System with Lewis Acid Active Centers for Treating MRSA-Infected Osteomyelitis.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Liu Panyue, Lu Shuxin, Cheng Hao, An Meiwen, Guo Jiqiang, Yao Xiaohong, Chu Paul K, Zhang Xiangyu
Аннотация
Conventional nanoenzymes for treating methicillin-resistant Staphylococcus aureus (MRSA)-infected osteomyelitis face serious limitations, including instability caused by valence cycling and impaired reactive oxygen species (ROS) generation by hypoxia. Here, we present Lewis acid nanoenzymes (Cu/ZM-Ca), which avoids valence cycling by through electron-pair-mediated hydrogen peroxide (H2O2) cleavage, exhibiting higher stability compared to compared to conventional Fenton catalysts. The ZSM-5 zeolite framework facilitates the synergizes of 3D Lewis acid centers with ultrasound to achieve on-demand generation of H2O2 through hydrolysis of calcium peroxide (CaO2) to enhance ROS generation under hypoxic conditions; and amplification of cavitation effects to achieve deep tissue penetration. The electron-pair catalytic mechanism is oxygen-independent, making Cu/ZM-Ca suitable for hypoxic deep-tissue infections. Density Functional Theory calculations reveal that the Lewis acid site reduces the activation energy of H2O2 through enhanced adsorption, allowing direct cleavage of the O─O bond without metal oxidation. This hybrid system reduces MRSA survival by 5-logs in 15 min through synergistic membrane disruption and metabolic blockade. In vivo, ultrasound-activated Cu/ZM-Ca cleared 99.5% of bacteria and resulted in an effective increase in bone regeneration (45.7% vs 24.5% BV/TV). This work establishes a novel class of hypoxia-resistant nanoenzymes based on Lewis acid catalysis, overcoming fundamental constraints of conventional ROS therapies.